Zentek Ltd 6-K, filed Apr 12, 2022
Zentek Ltd. (ZTEKF)
About this 6-K
Zentek Ltd filed this 6-K on April 12, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2022
Commission File Number: 001-41310
ZENTEK LTD.
(Registrant)
24 Corporate Court
Guelph, Ontario N1G 5G5 Canada
(Address of Principal Executive Offices)
Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
ZENTEK LTD. |
|
|
|
(Registrant) |
|
|
|
|
|
|
Date: April 12, 2022 |
By |
/s/ Brian Bosse |
|
|
|
Brian Bosse |
|
|
|
Chief Financial Officer |
EXHIBIT INDEX
|
Exhibit |
Description of Exhibit |
|
|
|
|
|
| 99.2 | News Release dated April 12, 2022 – Zentek Signs Supply Agreement with EkoMed Global Inc. to Manufacture ZenGUARD-enhanced PPE | |
Zentek Announces Start of Phase Two Testing of ZenGUARD™ -
Coated Filters Under ISC Testing Stream Contract
Guelph, ON - April 11, 2022, further to its press release dated November 30,2021, Zentek Ltd. ("Zentek" or the "Company") (Nasdaq: ZTEK; TSX-V: ZEN), a Canadian intellectual property development and commercialization company, announces that after successful completion of Phase 1 testing of its ZenGUARD™-coated HVAC filters, it will proceed to Phase 2 testing within its Innovation Solutions Canada ("ISC") Testing Stream contract.
Pursuant to its press release dated November 30, 2021, the Company announced that it has been awarded a research and development test contract through the ISC Testing Stream Call for Proposals to test ZenGUARD™-coated HVAC filters with interest from three different units within the National Research Council of Canada ("NRC"). The goal of the testing was to demonstrate: (i) a net reduction in the airborne viral load with ZenGUARD™ coating applied to standard filters; (ii) no modifications required to existing HVAC systems to achieve (i) above; (iii) no reduction in air flow rates, which means air exchange rates in the space will be unchanged; and (iv) no reduction in the air quality as the ZenGUARD™ coating will be tested to ensure it does not contribute particles into the air stream.
Phase 1 testing was conducted by CremCo Laboratories ("CCL") with assistance by the Aerospace Research Centre ("ARC"), a department of the National Research Council of Canada ("NRC"). A test rig was installed inside an aerobiology chamber to push air through HVAC filter material with test organisms to study how these live airborne organisms were reduced by the ZenGUARD™ coating. Testing involved multiple samples with repeated tests so that each filter's performance could be compared. It was determined that all Phase 1 targets were met including sufficient reduction in live airborne test organisms, no significant shedding of the ZenGUARD™ coating, and air flow rates that were not impacted by the coating.
"We are pleased to confirm that Phase 1 testing of our ZenGUARD™ coating was successful in reducing airborne organisms from passing through coated filter material while not inhibiting air flow," said Greg Fenton, CEO of Zentek. "Moving into Phase 2 testing of our patent-pending, antimicrobial coating in a real-world classroom environment is aimed to generate additional safety and efficacy data. The importance of indoor air quality and improving health is a top priority for numerous organizations globally - including the Canadian and U.S. governments - and this is an important commercialization milestone for Zentek in this critical area."
Phase 2 testing will commence shortly and be conducted at ARC with assistance from CCL. Airborne test organisms will again be used, and testing will be conducted in a controlled environment. The objective of Phase 2 testing is to demonstrate a reduction in live airborne surrogate contamination within a modular classroom environment, simulating a real- world environment.
By testing ZenGUARD™-coated HVAC filters, NRC is also expected to gain the knowledge and equipment to evaluate how airborne infectious diseases spread within aircraft cabins and other indoor spaces. The Testing Department has three units interested in Zentek's ZenGUARD™ innovation: Centre for Air Travel Research, Construction Research Centre, and Real Property Planning and Management.
The ISC Testing Stream aims to evaluate, test, and procure innovative late- stage pre-commercial prototypes, and create pools of pre-qualified innovations that Canada may select from to address a broad range of the Government of Canada organizations' requirements.
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website
at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile
at http://www.sedar.com/.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward- looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward- looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Zentek Signs Supply Agreement with EkoMed Global Inc.
to Manufacture ZenGUARD-enhanced PPE
Guelph, ON - April 12, 2022, Zentek Ltd. ("Zentek" or the "Company") (Nasdaq: ZTEK; TSX-V: ZEN), a Canadian intellectual property development and commercialization company, announces it has signed a definitive supply agreement with EkoMed Global Inc. ("EkoMed"), a globally integrated manufacturer and distributor of personal protective equipment ("PPE"), pursuant to which (i) Zentek will sell quantities of its proprietary ZenGUARD™ coating to EkoMed for use initially on EkoMed's surgical masks and potentially other PPE in the future, and (ii) Zentek will purchase surgical masks manufactured by EkoMed, to be treated with ZenGUARD™ coating and resold by Zentek.
"This agreement solidifies our relationship with an established and highly competitive player in the PPE space and a potential future innovation partner; both key elements of our global ZenGUARD™ sales strategy," said Greg Fenton, CEO of Zentek. "As we seek to gain access to new markets, reliable, high-capacity and high-quality production along with additional sales channels for our patent-pending ZenGUARD™ technology are crucial. We believe this agreement will establish a solid foundation for Zentek to expand access to ZenGUARD™ globally. As important, we look forward to working with the EkoMed team to explore incorporating ZenGUARD™ into other PPE products currently being manufacturing and commercialized by EkoMed."
EkoMed's focus is on designing and manufacturing a wide of range of single use PPE products for use in hospitals and other higher risk settings. It is headquartered and has manufacturing facilities in Turkey with the capacity to produce over 1.2 billion masks per year. It also has logistics and storage capacity in the U.S. and Canada to better serve its distribution partners and customers. With its highly efficient manufacturing process, five years in operation and with over 1000 employees, EkoMed is a well-established player in the PPE industry. It's success to date has produced business relationships with over 120 customers in countries around the world, and they continue to grow and add capacity.
"Our company's mission is to bring high-quality disposable products to hospitals, the healthcare market and other higher risk environment," said Annette Mitchell, Partner at EkoMed Global Inc. "We believe Zentek's unique ZenGUARD™ technology will be a valuable tool to help reduce the spread of pathogens in hospitals and other healthcare settings. While our initial focus will be on incorporating ZenGUARD™ into surgical masks, N95s and KN-95s, we look forward to working with the Zentek team towards potentially incorporating it into our other PPE products as well."
About Zentek Ltd.
Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZenGUARD™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed aptamer-based rapid pathogen detection technology.
About EkoMed
Headquartered in Istanbul, Turkey, EkoMed is a global integrated manufacturer of disposable healthcare products and service provider of medical technologies worldwide.
As EkoMed Health, it focuses on designing and manufacturing a wide of range of single use products that are especially used in hospitals and in surgical procedures.
All of the production processes are managed and monitored in accordance with ISO 9001, ISO 13795, ISO13485, CE, Health Canada and FDA standards and it has the full capacity to add more standards to make its manufacturing processes impeccable.
Its primary goal is to reliably provide quality products and continuous production within its high-capacity sterilization parks to end users and exceed customer expectations in the process.
EkoMed also has a manufacturing plant in İzmir, Turkey, warehouses and operational offices in USA and Canada.
For further information:
Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com
To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at http://www.sedar.com/.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.